Inari Medical (NASDAQ:NARI) Price Target Raised to $80.00 at Piper Sandler

Inari Medical (NASDAQ:NARI) had its target price hoisted by Piper Sandler from $52.00 to $80.00 in a research report report published on Tuesday,Benzinga reports. They currently have a neutral rating on the stock.

Several other research firms have also commented on NARI. Oppenheimer began coverage on shares of Inari Medical in a research note on Tuesday, December 17th. They set an “outperform” rating and a $75.00 target price for the company. Needham & Company LLC reiterated a “hold” rating on shares of Inari Medical in a research report on Tuesday, October 29th. Truist Financial raised their price objective on Inari Medical from $50.00 to $63.00 and gave the stock a “hold” rating in a research note on Wednesday, December 18th. Stifel Nicolaus assumed coverage on Inari Medical in a research report on Tuesday, September 17th. They set a “hold” rating and a $50.00 target price on the stock. Finally, Robert W. Baird reiterated a “neutral” rating and issued a $80.00 price target (down previously from $81.00) on shares of Inari Medical in a research report on Tuesday. Ten analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $68.00.

Inari Medical Trading Up 22.2 %

Shares of NASDAQ NARI opened at $79.45 on Tuesday. Inari Medical has a twelve month low of $36.73 and a twelve month high of $79.50. The firm has a 50-day moving average of $52.85 and a two-hundred day moving average of $48.92. The company has a market capitalization of $4.65 billion, a price-to-earnings ratio of -58.85 and a beta of 0.97.

Insider Buying and Selling

In other Inari Medical news, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the sale, the chief executive officer now owns 445,310 shares of the company’s stock, valued at $22,265,500. This trade represents a 0.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director William Hoffman sold 40,000 shares of the company’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $45.02, for a total transaction of $1,800,800.00. Following the completion of the transaction, the director now directly owns 601,233 shares in the company, valued at $27,067,509.66. This trade represents a 6.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 206,000 shares of company stock valued at $10,527,870. Corporate insiders own 10.60% of the company’s stock.

Institutional Investors Weigh In On Inari Medical

Institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC increased its holdings in Inari Medical by 67.2% in the third quarter. GAMMA Investing LLC now owns 1,177 shares of the company’s stock worth $49,000 after buying an additional 473 shares during the last quarter. KBC Group NV grew its position in Inari Medical by 39.0% in the third quarter. KBC Group NV now owns 1,774 shares of the company’s stock worth $73,000 after acquiring an additional 498 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its stake in shares of Inari Medical by 39.4% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after purchasing an additional 522 shares during the last quarter. Covestor Ltd raised its holdings in shares of Inari Medical by 63.5% during the 3rd quarter. Covestor Ltd now owns 2,384 shares of the company’s stock valued at $99,000 after purchasing an additional 926 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Inari Medical in the 2nd quarter valued at $104,000. 90.98% of the stock is currently owned by institutional investors and hedge funds.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.